Current classification of malignant tumours in gynecological oncology – part I

Česká verze

Authors: B. Sehnal ¹; D. Driák ¹ ; E. Kmoníčková ²; M. Dvorská ¹; M. Hósová ³; K. Citterbart ¹; M. Halaška ¹; D. Kolařík ¹
Authors place of work: Gynekologicko-porodnická klinika, 1. LF UK a FN Na Bulovce, Praha, přednosta prof. MUDr. M. Halaška, DrSc. ¹; Ústav radiační onkologie, 1. LF UK a FN Na Bulovce, Praha, přednosta prof. MUDr. J. Abrahámová, DrSc. ²; Patologicko-anatomické oddělení, 1. LF UK a FN Na Bulovce, Praha, primářka MUDr. K. Benková ³
Published in the journal: Ceska Gynekol 2011; 76(4): 279-284

Summary

Objective:
Review of new staging systems for gynaecological cancers and their impact on prognosis and planning treatment.

Design:
Review article.

Setting:
Department of Gynaecology and Obstetrics, First Faculty of Medicine and University Hospital Na Bulovce, Charles University, Prague.

Department of Radiotherapeutic Oncology, First Faculty of Medicine and University Hospital Na Bulovce, Charles University, Prague.

Department of Pathology, University Hospital Na Bulovce, Prague.

Results:
The main objectives of any good staging system – essential to an evidence-based approach to cancer – include planning treatment, providing an assessement of prognosis and the evaluation of the results of treatment. With this approach, the exchange of relevant information between oncological centers is facilitated, thus disseminating knowledge and stimulating research in other parts of the world. A good staging system must have three basic characteristics: validity, reliability, and practicality. The first staging system for gynaecological cancers appeared around the turn of the 20th century and was applied to carcinoma of the cervix uteri. Classifications for the other gynaecological malignancies were not created until the 1950s. Over the years, these staging classifications - with the exception of cervical cancer and gestational trophoblastic neoplasia - have shifted from a clinical to a surgical-pathological basis. Some changes, brought about through new findings, were approved by the FIGO in 2008 and published in 2009. The greatest changes were made in the new staging system for carcinoma of the vulva, while others were made in the new staging systems for carcinoma of the cervix and carcinoma of the endometrium. A new stanging system was also created for uterine sarcomas, based on the criteria used in other soft tissue sarcomas.

Conclusion:
As a result of the explosion of medical research in the field of oncology, the staging of some of the gynaecological cancers became outdated and did not give a good spread of prognostic groupings. Therefore, revised FIGO and TNM staging system has been structured to represent major prognostic factors in predicting patients’ outcomes and lending order to the complex dynamic behavior of gynaecological cancers. The purpose of a good staging system is to offer a classification of the extent of gynaecological cancer, in order to provide a method of conveying one’s clinical experience to others for the comparison of different treatment methods.

Key words:
staging, gynaecological oncology, FIGO, TNM.

Zdroje

1. Benedet, JL., Pecorelli, S. Why cancer staging? Int J Gynecol Obstet, 2006, 95, suppl. l, p. 3.

2. Benedet, JL. Conclusions. CME J Gynecol Oncol, 2001, 6, p. 270-273.

3. Benedet, JL. Indroduction. CME J Gynecol Oncol, 2001, 6, p. 229.

4. Bösze, P. Prognostic factors and staging: the role of molecular markers. CME J Gynecol Oncol, 2001, 6, p. 232-234.

5. Burger, MP., Hollema, H., Emanuels, AG., et al. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol, 1995, 57, 3, p. 327‑334.

6. Cavanagh, D., Roberts, WS., Bryson, SC., et al. Changing trends in the surgical treatment of invasive carcinoma of the vulva. Surg Gynecol Obstet, 1986, 162, 2, p. 164-168.

7. Cibula, D., Petruželka, L., et al. Onkogynekologie. 1. vyd. Praha: Grada, 2009, s 343.

8. Denoix, PF. Nomenclature des cancers. 1st ed. Paris: Bull Inst Nat Hyg, 1944, p. 69-73.

9. Fons, G., Hyde, SE., Buist, M., et al. The presence of bilateral positive lymph nodes in squamosus cell cancer of the vulva is not an independent prognostic variable for disease – specific survival. Int J Gynecol Cancer, 2009, 105, p. 103-104.

10. Gospodarowicz, MK., Benedet, L., Hutter, RV., et al. History and international development in cancer staging. Cancer Prev Control, 1998, 2, p. 262-268.

11. Gospodarowicz, MK., Miller, D., Groome, PA., et al. The proces for continuous improvement of the TMN classification. Cancer, 2004, 100, p. 1-5.

12. Hacker, NF., Berek, JS., Lagasse, LD., et al. Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol, 1983, 61, 4, p. 408-412.

13. Hacker, NF., Berek, JS. Practical gynecologic oncology. 4th ed. Philadephia: Lippincott Williams a Wilkins 2005, p. 543-581.

14. Hacker, NF. Revised FIGO staging for carcinoma of the vulva. Int J Gynaecol Obstet, 2009, 105, p. 105-106.

15. Hermanek, P. Why TNM system for staging of gynaecological tumours? CME J Gynecol Oncol, 2001, 6, p. 267-269.

16. Hoffman, JS., Kumar, NB., Morley, GW. Prognostic signifikance of groin lymph node metastases in squamosus carcinoma of vulva. Obstet Gynecol, 1985, 66, 3, p. 402-405.

17. Homesley, HD., Bundy, BN., Sedlis, A., et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival. Am J Obstet Gynecol, 1991, 164, 4, p. 997-1004.

18. Hopkins, MP., Reid, GC., Johnston, CM., Morley, GW. A comparison of staging systems for squamous cell carcinoma of the vulva. Gynecol Oncol, 1992, 47, 1, p. 34-37.

19. Kottmeier, HL. Annual report on the results of treatment in gynecological cancer. FIGO, 1982, Eighteenth volume.

20. Lataifeh, I., Nascimento, MN., Nicklin, JL., et at. Patterns of recurrence and disease-free survival in advanced squamosus cell carcinoma of the vulva. Gynecol Oncol, 2004, 95, 3, p. 701-705.

21. Mackillop, WJ., O’Sullivan, B., Gospodarowicz, M. The role of cancer staging in evidence-based medicine. Cancer Prev Control, 1998, 2, 6, p. 269-277.

22. Marsden, DE., Hacker, NF. Controversies and new trends in staging vulvar and vaginal carcinoma. CME J. Gynecol Oncol, 2001, 6, p. 235-239.

23. Morley, GW. Infiltrative carcinoma of the vulva: result of surgical treatment. Am J Obstet Gynecol, 1976, 124, 8, p. 874‑888.

24. O’Sullivan, B., Gospodarowicz, M., Mckillop, WJ. Cancer staging. Cancer Prev Control, 1998, 2, 6, p. 260-261.

25. Odicino, F., Pecorelli, S., Zigliani, L., Creasman, WT. History of the FIGO cancer staging system. Int J Gynecol Obstet, 2008, 101, p. 205-210.

26. Origoni, M., Sideri, M., Garsia, S., et at. Prognostic value of pathological patterns of lymph node positivity in squamosus cell carcinoma of the vulva stage III and IVA FIGO. Gynecol Oncol, 1992, 45, 3, p. 313-316.

27. Paladini, D., Cross, P., Lopes, A., Monaghan, JM. Prognostic significance of lymph node variables in squamosus cell carcinoma of the vulva. Cancer, 1994, 74, 9, p. 2491-2496.

28. Pecorelli, S., Ngan, HYS., Hacker, NF. Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers. A collaboration between FIGO and IGCS. 3rd ed. London: FIGO, 2006.

29. Pecorelli, S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet, 2009, 105, p. 103-104.

30. Pettersson, F. Annual report on the results of treatment in gynecological cancer. FIGO, 1988, Twentieth volume.

31. Pettersson, F. Annual report on the results of treatment in gynecological cancer. FIGO, 1985, Nineteenth volume.

32. Raspagliesi, F., Hanozet, F., Ditto, A., et al. Clinical and pathologic prognostic factors in squamosus cell carcinoma of the vulva. Gynecol Oncol, 2006, 102, 2, p. 333-337.

33. Tantipalakorn, C., Robertson, G., Marsden, DE., et al. Outcome and patterns of recurrence for FIGO stages I and II squamosus cell vulvar cancer. Obstet Gynecol, 2009, p. 113.

34. TNM klasifikace zhoubných novotvarů. 7. vyd. Chichester, UK: Wiley-Blackwell, 2009, česká verze 2011, p. 17-29, 159-163.

35. van der Velden, J., van Lindert, AC., Lammes, FB., et al. Extracapsular growth of lymph node metastases in squamous cell carcinoma of the vulva. Cancer, 1995, 75, 12, p. 2885-2890.

36. van Trappen, PO., Jacobs, IJ. Controversies and new trends in staging ovarian and Fallopian tube carcinoma. CME J Gynecol Oncol, 2001, 6, p. 260-266.

37. www.figo.org.

38. www.nccn.org.